Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.
The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.
Grifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.